ionis pharmaceuticals

News

Ionis Pharmaceuticals, FDA

US FDA approves Ionis' drug for rare genetic disorder

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder.

PharmExec · 5h

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and pediatric patients aged 12 years and older.

GlobalData on MSN · 11h

FDA approves Ionis’ donidalorsen for HAE attack prevention

Dawnzera is designed to inhibit plasma prekallikrein, a significant activator of the inflammatory mediators that cause acute HAE attacks. This 80mg dose of the medicine is self-administered through a subcutaneous autoinjector,

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

BioSpace9h

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high ...

TipRanks on MSN12h

Ionis Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $65 and keeps a Buy rating on the shares following FDA ...

Asianet Newsable on MSN18h

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

BofA Securities raised its target to $64 with a ‘Buy’ rating, while Stifel lifted its target to $43 with a ‘Hold,’ both ...

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.

Hosted on MSN1d

Ionis Pharmaceuticals trading halted, news pending

09:38 EDT Ionis Pharmaceuticals (IONS) trading halted, news pending Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results